Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases [Yahoo! Finance]
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Yahoo! Finance
AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases. The trial is being conducted by Asahi Kasei Therapeutics Corp., its pharmaceutical subsidiary based in Japan. AK1940 was discovered through a joint research initiative with PeptiDream Inc. and represents an important facet of Asahi Kasei's strategy to strengthen its pharmaceutical development pipeline and drive long-term growth. Preclinical studies have been successfully completed, and the Phase I trial began on April 19, 2026, in Japan. The trial will assess the pharmacokinetic profile, safety, and tolerability of single and multiple subcutaneous doses of AK1940 in healthy volunteers. AK1940 is a selective tumor necrosis factor (TNF) receptor 1 antagonist. Preclinical studies suggest that AK1940 is highly selective for TNF receptor 1 and showed activity in animal models of inflammatory disease. By targeting this receptor, AK1940 has the
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy [Yahoo! Finance]Yahoo! Finance
- Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical StrategyBusiness Wire
- Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune DiseasesBusiness Wire
- Asahi Kasei (AHKSY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Is It Too Late To Consider Asahi Kasei (TSE:3407) After A 73% One-Year Surge? [Yahoo! Finance]Yahoo! Finance